ArticleEuropean journal of cancer care2017
Financial toxicity: a potential side effect of prostate cancer treatment among Australian men.
Article in European journal of cancer care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 8 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Towards the assessment of financial distress among cancer patients: a conceptual model of the financial effects of a tumour disease.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Describing financial toxicity among cancer patients in different income countries: a systematic review and meta-analysis.Frontiers in public health · 2023Pooled it
- The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review.Current oncology (Toronto, Ont.) · 2021Pooled it
- Australian Experiences of Out-of-Pocket Costs and Financial Burden Following a Cancer Diagnosis: A Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Financial toxicity and employment status in cancer survivors. A systematic literature review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Pooled it
- Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Pooled it
- Work after prostate cancer: a systematic review.Journal of cancer survivorship : research and practice · 2019Pooled it
- A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can't Pay the Co-Pay.The patient · 2017Pooled it
- The impact of adding cost information to a conversation aid to support shared decision making about low-risk prostate cancer treatment: Results of a stepped-wedge cluster randomised trial.Health expectations : an international journal of public participation in health care and health policy · 2023Trial
- Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.Prostate cancer and prostatic diseases · 2021Trial
- Care to Quit: a stepped wedge cluster randomised controlled trial to implement best practice smoking cessation care in cancer centres.Implementation science : IS · 2021Trial
- Treatment utilisation for Aboriginal and Torres Strait Islander people diagnosed with prostate cancer in Australia: a population-based study.The Lancet regional health. Western Pacific · 2026Article
- Exploring the barriers to optimal survivorship care for people living with Cancer in NSW.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Prostate Cancer Specialist Nursing Program: A Social Return on Investment Analysis Value for Money of the Prostate Cancer Specialist Nursing Program.Psycho-oncology · 2025Article
- Article
- PaSTe. Blockade of the Lipid Phenotype of Prostate Cancer as Metabolic Therapy: A Theoretical Proposal.Current medicinal chemistry · 2024Review
- Financial toxicity experienced by rural Australian families with chronic kidney disease.Nephrology (Carlton, Vic.) · 2023Article
- Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China.Journal of cancer research and clinical oncology · 2023Article
- 'What price do you put on your health?': Medical cannabis, financial toxicity and patient perspectives on medication access in advanced cancer.Health expectations : an international journal of public participation in health care and health policy · 2023Article
- Disease mapping: Geographic differences in population rates of interventional treatment for prostate cancer in Australia.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to understand the extent, nature and variability of the current economic burden of prostate cancer among Australian men. An online cross-sectional survey was developed that combined pre-existing economic measures and new questions. With few exceptions, the online survey was viable and acceptable to participants. The main outcomes were self-reported out-of-pocket costs of prostate cancer diagnosis and treatment, changes in employment status and household finances. Men were recruited from prostate cancer support groups throughout Australia. Descriptive statistical analyses were undertaken. A total of 289 men responded to the survey during April and June 2013. Our study found that men recently diagnosed (within 16 months of the survey) (n = 65) reported spending a median AU$8000 (interquartile range AU$14 000) for their cancer treatment while 75% of men spent up to AU$17 000 (2012). Twenty per cent of all men found the cost of treating their prostate cancer caused them 'a great deal' of distress. The findings suggest a large variability in medical costs for prostate cancer treatment with 5% of men spending $250 or less in out-of-pocket expenses and some men facing very high costs. On average, respondents in paid employment at diagnosis stated that they had retired 4-5 years earlier than planned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.